<DOC>
	<DOCNO>NCT01945788</DOCNO>
	<brief_summary>The primary objective study compare efficacy safety two formulation teriparatide 20 mcg/day plus calcium vitamin D postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>Clinical Comparison Efficacy Safety Two Teriparatide Formulations : Osteofortil Forteo</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Fractures , Spontaneous</mesh_term>
	<mesh_term>Osteoporotic Fractures</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>I . Female . II . Age great equal 50 less 81 year . III . Last menstrual period least one year prior sign inform consent . IV . Osteoporosis . Defined presence : BMD DEXA Tscore 2.5 low lumbar spine Tscore lumbar spine , femoral neck total hip 2.0 , together one vertebral fracture document lateral spine radiograph . V. Have sign informed consent I Bone alkaline phosphatase blood normal limit without explanation . II . Liver disease ( AST ALT &gt; 2 x ULN ) . III . Renal disease ( serum creatinine &gt; 2.0 mg / dl ) / creatinine clearance &lt; 30 ml / min IV . Hypercalcemia ( [ Ca ] &gt; 10.5 mg / dL ) . Patients elevate PTH presence albumincorrected calcium within normal value reevaluate . V. Elevated blood PTH ( [ PTH ] &gt; 65 pg / ml ) Patients elevate PTH presence albumincorrected calcium within normal value reevaluate . VI . • Deficiency vitamin D ( 25OH vitamin D &lt; 16 ng / ml ) excess vitamin D ( 80 ng / ml blood ) . Patients meet inclusion criterion vitamin D may receive supplement ( vitamin D ) reevaluate . VII . • Anemia ( hematocrit &lt; 32 % ) . VIII . • History cancer ( except basal cell carcinoma ) radiotherapy . IX . Severe cardiopulmonary disease , include coronary heart disease : unstable angina , heart failure class III IV condition investigator believe may prevent participation safely complete protocol procedure . X . Major psychiatric disease opinion investigator , would prevent give properinformed consent complete study procedure . XI . Excessive alcohol substance abuse opinion investigator prevents give informed consent complete proper protocol procedure . XII . Congenital acquire bone disease , osteoporosis ( include osteomalacia , hyperparathyroidism Paget 's disease ) XIII . Regarding history ingestion oral bisphosphonates : After assessment adequate adherence ( compliance great 75 % ) , patient receive six month treatment , bisphosphonatefree period six month . If take six month , bisphosphonatefree period must 12 month . XIV . Current within last 3 month study entry estrogen use , selective estrogen receptor modulators use calcitonin use therapeutic dos . XV . Current use systemic corticosteroid ( oral parenteral ) 14 day last 6 month . Vaginal estrogen isoflavones permit . XVI.Current previous use teriparatide , PTH analogues patch injectables , strontium , fluorine intravenous bisphosphonate therapeutic dose , XVII . Known hypersensitivity pharmaceutical derive bacterial cell . XVIII . Hypersensitivity teriparatide excipients . XIX.Nephrolithiasis urolithiasis activity , accord investigator opinion 5 year prior randomization . XX.Inflammatory bowel disease , malabsorption syndrome sign intestinal calcium malabsorption XXI . Treatment androgens anabolic steroid 6 month prior randomization . XXII . Any medical condition investigator opinion would contraindicate treatment investigational drug . XXIII . Treatment coumarin indandione derivatives 3 month prior randomization treatment heparin ( dos &gt; 10,000 U / day ) 30 day 6 month prior randomization . XXIV.Treatment drug know affect bone metabolism , therapeutic dos , 6 month prior randomization . XXV.Treatment investigational drug month prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>